Automate Your Wheel Strategy on PASG
With Tiblio's Option Bot, you can configure your own wheel strategy including PASG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PASG
- Rev/Share 1.0136
- Book/Share 12.0728
- PB 0.6129
- Debt/Equity 0.6464
- CurrentRatio 3.0461
- ROIC -0.9806
- MktCap 23522136.0
- FreeCF/Share -11.3925
- PFCF -0.6515
- PE -0.4124
- Debt/Assets 0.3123
- DivYield 0
- ROE -1.0387
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PASG | Rodman & Renshaw | -- | Buy | -- | $7 | Sept. 3, 2024 |
News
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), …
Read More
Passage Bio to Participate in Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Read More
About Passage Bio, Inc. (PASG)
- IPO Date 2020-02-28
- Website https://www.passagebio.com
- Industry Biotechnology
- CEO William Chou
- Employees 60